In addition to these effects of pasireotide on GH and IGF-I, pasireotide has also been reported to be associated with hyperglycemia and weight loss in patients with Cushing's disease (42) or metastatic gastrointestinal NETs (35) that received pasireotide treatment. Here, IGF1 is linked to Hyperglycemia.